5-Chloro-8-quinolyl acrylate | 34462-99-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-Chloro-8-quinolyl acrylate
• 英文别名: 5-Chloro-8-quinolinyl acrylate；(5-chloroquinolin-8-yl) prop-2-enoate
• CAS: 34462-99-2
• 化学式: C₁₂H₈ClNO₂
• 分子量: 233.654
• InChiKey: MEUOMPOWZFJBCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Chloro-8-quinolyl acrylate 、 bis(perfluoro-2-N-propoxypropionyl)peroxide 生成 Polymer, M_n = 2200, M_w/M_n = 1.10
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• SURFACE COATING PROCESSES AND USES OF SAME
  申请人：Haverty Donncha

  公开号：US20100211158A1

  公开（公告）日：2010-08-19

  The present application relates to processes for coating surfaces and provides a method of forming a coating on a surface. The method involves bombarding a surface with particles having sufficient energy to remove surface material. At the same time an aerosol is delivered to the surface. The cooperative action of the particles impinging on the surface and the presence of the aerosol contribute to the formation of a coating on the surface.
• COMPOSITIONS AND METHODS FOR INHIBITION AND INTERRUPTION OF BIOFILM FORMATION
  申请人：DENTSPLY SIRONA INC.

  公开号：US20170280725A1

  公开（公告）日：2017-10-05

  Compositions and methods for inhibiting and interrupting biofilm formation, and for destabilizing established biofilms are provided, the novel compositions including polymeric resins and monomeric non-polymerizable and polymerizable resins. More particularly, the compositions and methods enable the protection and removal of biofilms from surfaces in the context of medical, consumer, domestic, food service, environmental and industrial applications, where the effects constitute beneficial and desirable biofilm attenuating activity.
• BIOCIDAL-FUNCTIONALIZED CORROSION INHIBITORS
  申请人：International Business Machines Corporation

  公开号：US20200063270A1

  公开（公告）日：2020-02-27

  In one aspect, the disclosure is directed to a biocidal-functionalized corrosion inhibitor. The biocidal-functionalized corrosion inhibitor includes a biocidal group linked to a corrosion inhibitor group. The corrosion inhibitor group includes a triazole ring for copper (Cu) corrosion inhibition. In another aspect, the disclosure is directed to a process of forming a biocidal-functionalized corrosion inhibiting small molecule. In yet another aspect, the disclosure is directed to a process of forming a biocidal-functionalized corrosion inhibiting polymeric material.
• [EN] POLYMER AND ITS USE<br/>[FR] POLYMERE ET SON UTILISATION
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002032974A2

  公开（公告）日：2002-04-25

  A polymer or its salt which is obtainable by polymerization of a monomer of the formula (I) or its salt in the presence of a radical initiator, or by polymerization of a monomer of the formula (I) or its salt with a monomer of the formula (II) or its salt in a molar ratio of (I): (II) being 1:0.1 to 1:25 in the presence of a radical initiatorwherein R1 and R3 are each hydrogen atom or lower alkyl group, R2 and R4 are each acyl group,aliphatic silyl group,amino lower alkyl group which may have one or more suitable substituent(s),heterocyclic group which may have one or more suitable substituent(s) orcarboxy group esterified by the residue of cellulose optionally substituted with one or more lower alkyl and/or lower alkenoyl.
• [EN] COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA OR HYPERGLYCEMIA<br/>[FR] COMPOSITION POUR PREVENIR OU TRAITER L'HYPERLIPIDEMIE OU L'HYPERGLYCEMIE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2003028739A2

  公开（公告）日：2003-04-10

  A composition for preventing or treating hyperlipidemia (e.g., hypercholesterolemia, hypertriglyceridemia) or hyperglycemia comprising a polymer or its salt which is obtainable by polymerization of a monomer of the formula (I) or its salt in the presence of a radical initiator, or by polymerization of a monomer of the formula (I) or its salt with a monomer of the formula (II) or its salt in a molar ratio of (I) : (II) being 1:0.1 to 1:25 in the presence of a radical initiator wherein R1, R2, R3, R4 are as defined in the description as an active ingredient, in association with a pharmaceutically acceptable, non-toxic carrier or excipient.